基于微 RNA 的败血症治疗方法的临床前研究:范围综述

Oxygen Pub Date : 2024-01-29 DOI:10.3390/oxygen4010002
A. Ektesabi, Julia Simone, C. Vaswani, Greaton W. Tan, Yanbo Wang, Jacqueline L. Pavelick, Xiao Wu, Janice Tai, Sahil Gupta, James N Tsoporis, Claudia C. dos Santos
{"title":"基于微 RNA 的败血症治疗方法的临床前研究:范围综述","authors":"A. Ektesabi, Julia Simone, C. Vaswani, Greaton W. Tan, Yanbo Wang, Jacqueline L. Pavelick, Xiao Wu, Janice Tai, Sahil Gupta, James N Tsoporis, Claudia C. dos Santos","doi":"10.3390/oxygen4010002","DOIUrl":null,"url":null,"abstract":"Background: Sepsis is a severe and life-threatening condition triggered by a dysregulated response to infection, leading to organ failure and, often, death. The syndrome is expensive to treat, with survivors frequently experiencing reduced quality of life and enduring various long-term disabilities. The increasing understanding of RNA, RNA biology, and therapeutic potential offers an unprecedented opportunity to develop innovative therapy. Objective: This study is a scoping review focusing on pre-clinical studies of microRNA (miRNA)-based therapies for sepsis. Methodology: A scoping review. The search strategy identified papers published in PubMed until 15 October 2023, using the keywords (microRNA) AND (sepsis) AND (animal model). Inclusion criteria included papers that used either gain- or loss-of-function approaches, excluding papers that did not focus on microRNAs as therapy targets, did not include animal models, did not show organ failure-specific assessments, and focused on microRNAs as biomarkers. The PRISMA-ScR guideline was used in this study. Results: A total of 199 articles were identified that featured the terms “microRNA/miRNA/miR”, “Sepsis”, and “animal model”. Of these, 51 articles (25.6%) employed miRNA-based therapeutic interventions in animal models of sepsis. Of these, 15 studies extended their inquiry to include or reference human clinical data. Key microRNAs of interest and their putative mechanisms of action in sepsis are highlighted. Conclusions: The body of work examined herein predominantly addresses various dimensions of sepsis-induced organ dysfunction, supporting the emerging role of miRNAs as potential therapeutic candidates. However, nearly 5% of papers on miR-based therapy have been retracted over the past 5 years, raising important concerns regarding the quality and complexity of the biology and models for assessing therapeutic potential.","PeriodicalId":516952,"journal":{"name":"Oxygen","volume":"75 48","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pre-Clinical Studies of MicroRNA-Based Therapies for Sepsis: A Scoping Review\",\"authors\":\"A. Ektesabi, Julia Simone, C. Vaswani, Greaton W. Tan, Yanbo Wang, Jacqueline L. Pavelick, Xiao Wu, Janice Tai, Sahil Gupta, James N Tsoporis, Claudia C. dos Santos\",\"doi\":\"10.3390/oxygen4010002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Sepsis is a severe and life-threatening condition triggered by a dysregulated response to infection, leading to organ failure and, often, death. The syndrome is expensive to treat, with survivors frequently experiencing reduced quality of life and enduring various long-term disabilities. The increasing understanding of RNA, RNA biology, and therapeutic potential offers an unprecedented opportunity to develop innovative therapy. Objective: This study is a scoping review focusing on pre-clinical studies of microRNA (miRNA)-based therapies for sepsis. Methodology: A scoping review. The search strategy identified papers published in PubMed until 15 October 2023, using the keywords (microRNA) AND (sepsis) AND (animal model). Inclusion criteria included papers that used either gain- or loss-of-function approaches, excluding papers that did not focus on microRNAs as therapy targets, did not include animal models, did not show organ failure-specific assessments, and focused on microRNAs as biomarkers. The PRISMA-ScR guideline was used in this study. Results: A total of 199 articles were identified that featured the terms “microRNA/miRNA/miR”, “Sepsis”, and “animal model”. Of these, 51 articles (25.6%) employed miRNA-based therapeutic interventions in animal models of sepsis. Of these, 15 studies extended their inquiry to include or reference human clinical data. Key microRNAs of interest and their putative mechanisms of action in sepsis are highlighted. Conclusions: The body of work examined herein predominantly addresses various dimensions of sepsis-induced organ dysfunction, supporting the emerging role of miRNAs as potential therapeutic candidates. However, nearly 5% of papers on miR-based therapy have been retracted over the past 5 years, raising important concerns regarding the quality and complexity of the biology and models for assessing therapeutic potential.\",\"PeriodicalId\":516952,\"journal\":{\"name\":\"Oxygen\",\"volume\":\"75 48\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oxygen\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/oxygen4010002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oxygen","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/oxygen4010002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:败血症是一种严重的危及生命的疾病,由对感染的失调反应引发,导致器官衰竭,并常常导致死亡。该综合征的治疗费用高昂,幸存者往往生活质量下降,并伴有各种长期残疾。人们对 RNA、RNA 生物学和治疗潜力的了解日益加深,为开发创新疗法提供了前所未有的机会。研究目的本研究是一篇范围综述,重点关注基于微 RNA (miRNA) 的败血症疗法的临床前研究。研究方法:范围界定综述。检索策略是使用关键词(microRNA)和(败血症)和(动物模型),查找 2023 年 10 月 15 日前发表在 PubMed 上的论文。纳入标准包括使用功能增益或功能缺失方法的论文,但不包括未将 microRNA 作为治疗靶点、未纳入动物模型、未显示器官衰竭特异性评估以及未将 microRNA 作为生物标志物的论文。本研究采用了 PRISMA-ScR 指南。研究结果共鉴定出 199 篇以 "microRNA/miRNA/miR"、"败血症 "和 "动物模型 "为关键词的文章。其中,51 篇文章(25.6%)在败血症动物模型中采用了基于 miRNA 的治疗干预措施。其中,15 项研究将调查范围扩大到人类临床数据或参考了人类临床数据。重点介绍了主要的microRNA及其在败血症中的作用机制。结论:本文所探讨的研究主要涉及脓毒症诱发器官功能障碍的各个层面,支持 miRNA 作为潜在候选疗法的新兴作用。然而,在过去 5 年中,近 5% 基于 miR 治疗的论文被撤回,这引起了人们对评估治疗潜力的生物学和模型的质量和复杂性的关注。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pre-Clinical Studies of MicroRNA-Based Therapies for Sepsis: A Scoping Review
Background: Sepsis is a severe and life-threatening condition triggered by a dysregulated response to infection, leading to organ failure and, often, death. The syndrome is expensive to treat, with survivors frequently experiencing reduced quality of life and enduring various long-term disabilities. The increasing understanding of RNA, RNA biology, and therapeutic potential offers an unprecedented opportunity to develop innovative therapy. Objective: This study is a scoping review focusing on pre-clinical studies of microRNA (miRNA)-based therapies for sepsis. Methodology: A scoping review. The search strategy identified papers published in PubMed until 15 October 2023, using the keywords (microRNA) AND (sepsis) AND (animal model). Inclusion criteria included papers that used either gain- or loss-of-function approaches, excluding papers that did not focus on microRNAs as therapy targets, did not include animal models, did not show organ failure-specific assessments, and focused on microRNAs as biomarkers. The PRISMA-ScR guideline was used in this study. Results: A total of 199 articles were identified that featured the terms “microRNA/miRNA/miR”, “Sepsis”, and “animal model”. Of these, 51 articles (25.6%) employed miRNA-based therapeutic interventions in animal models of sepsis. Of these, 15 studies extended their inquiry to include or reference human clinical data. Key microRNAs of interest and their putative mechanisms of action in sepsis are highlighted. Conclusions: The body of work examined herein predominantly addresses various dimensions of sepsis-induced organ dysfunction, supporting the emerging role of miRNAs as potential therapeutic candidates. However, nearly 5% of papers on miR-based therapy have been retracted over the past 5 years, raising important concerns regarding the quality and complexity of the biology and models for assessing therapeutic potential.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信